Browse the evidence

Diabetic patients with BMI >40 kg/m² had significantly higher %EWL than patients with BMI ≤40 at 12 and 24 months.

Patients with higher BMI may achieve better weight loss results post-surgery, which can guide treatment decisions.

The online exercise program had good feasibility and adherence, with 97% attendance and 98% participant satisfaction.

Practitioners can consider online exercise programs as a feasible option for engaging older adults.

An increase of 1 serving/day of low calorie sweetened beverages (LCSBs) is associated with reduced body weight by −0.07 kg and waist circumference by −1.35 cm.

Increasing LCSB intake may help in weight management for individuals at risk for or with diabetes.

People with physical disabilities (PWD) report more sedentary time compared to people without disabilities (PWoD) (β = 0.34; 95 % CI = 0.16-0.52, p < 0.001).

Practitioners should be aware that PWD may require tailored interventions to reduce sedentary behavior.

PWD have greater odds of reporting zero total physical activity compared to PWoD (OR = 5.18, 95 % CI = 2.19-12.24, p < 0.001).

Interventions for PWD should focus on increasing overall physical activity levels.

The Brain and Body Health (BB-Health) study aims to demonstrate the feasibility of a multicomponent nutritional supplement (MCNS) and weight loss (WL) intervention for older adults with obesity.

Practitioners may consider the potential of MCNS and WL interventions for older adults with obesity.

Including simple variables such as body mass and sex in regression models improved the predictions of accelerometer-assessed TEE.

Incorporating individual characteristics like body mass and sex can enhance the accuracy of TEE assessments using accelerometers.

Overfeeding led to an average body weight gain of 7.3 ± 0.4 kg.

Practitioners should be aware that overfeeding can lead to significant weight gain.

Adipocyte browning enhances energy expenditure, improves insulin sensitivity, and mitigates lipid accumulation.

Adipocyte browning could be targeted in therapies for obesity and metabolic diseases.

Bariatric surgery is associated with a 42.4% reduction in fat mass (FM) at 6 months, 49.7% at 12 months, and 49.7% at 24 months.

Bariatric surgery significantly reduces fat mass in patients over a 24-month period.

Both bariatric surgery and GLP-1RA treatment improve the fat-free mass (FFM) to fat mass (FM) ratio.

Both interventions are effective in improving body composition ratios.

No significant adverse events were recorded during the study.

The combination appears to be safe for use in the studied population.

Traditional interventions related to diet and exercise have fallen short in addressing obesity.

New treatment approaches may be necessary to effectively manage obesity.

Patients show a strong commitment to obtaining and maintaining weight-loss medication despite disruptions to their daily lives.

Health care providers should recognize the dedication of patients in managing their weight-loss treatment.

Health care professionals align patients' expectations for immediate weight loss while navigating moral reasoning about weight loss methods.

Practitioners should be aware of the expectations patients have and the ethical considerations in weight-loss discussions.

Bariatric medicine includes a range of medical and surgical interventions to address obesity.

Practitioners should consider a variety of interventions when managing obesity.

Among 1,059,605 Veterans with incident prediabetes, 12,009 (1.1%) were prescribed metformin during an average 3.4 years of observation after diagnosis.

Practitioners should note that metformin is prescribed to a small percentage of Veterans with prediabetes.

Over 20% of Veterans with prediabetes attended a comprehensive structured lifestyle modification clinic or program.

Practitioners should encourage participation in lifestyle modification programs for Veterans with prediabetes.

Gastrointestinal adverse events were recorded in most studies but did not impact overall weight loss.

Practitioners should be aware of potential GI side effects but can consider semaglutide effective for weight loss despite these events.

Recommendations for collaborative action include developing obesity education and care standards that incorporate patients' perspectives.

Healthcare systems should prioritize patient-centered approaches in obesity care.

Emerging therapies for genetic and syndromic obesities include approved treatments like setmelanotide and semaglutide.

Practitioners should consider the use of approved therapies like setmelanotide and semaglutide in treatment plans.

Patients with obesity are at increased risk for developing type 2 diabetes, heart attack, stroke, liver disease, and obstructive sleep apnea.

Healthcare providers should monitor and address these risks in patients with obesity.

The treatment adherence rate was 84.6%, with 170 out of 201 patients completing the therapy.

High adherence suggests that the therapy is well-received by patients.

Among 11,700 reports from July 2009 to April 2024, 13 incidents related to GLP-1 agonist use were identified, including seven cases concerning aspiration.

Clinicians should be aware of the potential aspiration risks associated with GLP-1 agonist use in the perioperative setting.